

ASX Announcement 26 April 2022

OPTISCAN APPOINTS KEY MANAGEMENT STAFF

The Board of Optiscan Imaging Limited (ASX: OIL) ('the Company' or 'Optiscan') is pleased to announce the appointment of new key management staff.

The three new appointments across marketing, commercial operations and finance reflect the exciting stage that the Company is embarking on. Optiscan's unique endomicroscopic technology is nearing the commercialisation phase and in preparedness for this significant growth period we are making three key appointments. Once FDA approval is received, these key appointments, together with the existing management team, will underpin the Company's global preparedness to commercialise and market Optiscan's unique technology.

The Company has appointed Mr Andrew Barker as its new Marketing Manager. An accomplished marketer, Andrew brings over 20 years of marketing experience from Smith & Nephew, Incitec Pivot, ConvaTec, Ansell, Seqirus (a CSL company) and most recently Latitude Financial Services. Andrew is a graduate of the University of Sheffield, with a Chartered Institute of Marketing qualification from the University of Hull, UK and will be responsible for developing and executing Optiscan's global marketing strategies.

To help grow the commercial position of the company, Optiscan has appointed Mr Steven Smart as its new Commercial Manager. Steven's 25 years' experience spans multiple industries focused on sales and commercialisation with roles at Roche Diagnostics, GlaxoSmithKline, Thermo Fisher Scientific, Hollister, and more recently Independence Australia. Steven graduated from Swinburne University with a degree in Biophysics and Instrument Science, and holds a Graduate Diploma of Marketing from Monash University.

To strengthen its financial position as it prepares for international growth, the Company has appointed Ms Daisy Liu as its new Finance Manager. Daisy brings with her prior experiences at Bosch, Rubicon Water, and Jetstar Airways working across multiple geographical locations and tax jurisdictions. Daisy is a graduate of Macquarie University, and is a full member of CPA Australia as well as CIMA. In her role, Daisy will be responsible for the financial reporting systems and structures of the Company including off-shore activities.

Optiscan CEO & Managing Director Prof Camile Farah said "I am excited to welcome Andrew, Steven and Daisy to the team as the Company accelerates its growth and international expansion. Their input will be crucial as Optiscan prepares to take its new cutting-edge clinical devices to market".

- ends -

This announcement has been authorised for release by the Board of Optiscan.

For investor queries, please contact:

Prof Camile Farah
CEO & Managing Director – Optiscan Imaging Ltd
E: cfarah@optiscan.com

About Optiscan

Optiscan is a global leader in the development, manufacturing and commercialisation of microscopic imaging and related technologies for preclinical, translational and medical applications. Based in Victoria, Australia, Optiscan was established in 1994, and listed on the ASX in 1997 (ASX: OIL). OptiScan has developed and patented endomicroscopic technology which enables real-time, 3D, 'in vivo' imaging of human tissue at the cellular level allowing instant "digital biopsies" for cancer screening, diagnoses and in surgery.

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of OptiScan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate", "believe", "could", "estimate", "expect", "future", "intend", "may", "opportunity", "plan", "potential", "project", "seek", "will" and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of OptiScan that could cause actual results to differ from the results expressed or anticipated in these statements.